Objective To estimate the association between the use of sodium glucose co-transporter-2 (SGLT2)
inhibitors and postmarket harms as identified by drug regulatory agencies. Design …

Background Phase two of cannabis legalisation in Canada brought cannabis vaping products
to the market. This decision was controversial due to an outbreak of vaping cannabis use-…

Background An increased understanding of the genetic basis of disease creates a demand
for personalized medicine and more genetic testing for diagnosis and treatment. The …

Background Cannabis legalization is intended to protect the public from potential harm by
restricting access and promoting greater awareness of cannabis-related risks. Youth are at a …

Legalization of non-medical cannabis in Canada was intended to protect youth health and
safety by limiting access and raising awareness of safety and risks. The purpose of this …

Background: The sodium glucose cotransporter-2 (SGLT2) inhibitors are a novel group of
drugs for treatment of type 2 diabetes mellitus. We investigated whether there is a dose–…

… Author links open overlay panel Jennifer R. Donnan BScPharm, MSc, MBA a , Karissa
Johnston PhD a , Eugene Chibrikov PhD a , Carlo A. Marra BScPharm, PharmD, PhD a b , Kris …

Aims Mixed evidence exists for the effect of incretin-based therapies on osteoporosis in type-2
diabetes. Therefore, we conducted a cohort study to determine the association between …

Background Emerging adults (EAs) have the highest rates of cannabis consumption in Canada
and are vulnerable to the potential impacts of frequent cannabis consumption. This study …

Objective: Cannabis was legalized for nonmedical use in Canada in 2018. However, with a
long-established illegal market, it is important to understand cannabis consumers’ …